Comments: No Comments
Stuart Therapeutics, Inc. (STUART), the leader in the application of collagen mimetic peptide (CMP) technology for ophthalmology, today announced that it has been selected as a presenter at the Association for Research of Vision and Ophthalmology (ARVO) 2020 Annual Meeting in Baltimore, Maryland, May 3rd through 7th at the Baltimore Convention Center. The presentation is titled “Collagen Mimetic Peptides (CMPs) as a bioengineering tool to repair damaged collagen substrates and basement membranes and facilitate corneal epithelial growth,” and will address the mechanism of action, speed of results, and overall impact on the eye of STUART’s PolyColTM (PolyCol) CMP technology, a rapid, effective reparative for ocular surface indications. Bob Baratta, MD, STUART’s Chairman and Chief Medical Officer will deliver the presentation on Sunday, May 3rd, between 8:00 and 9:45 AM and between 5:00 and 6:00 PM. The STUART presentation number is: 173 – A0207, and will be in the Corneal Epithelial Wound Healing Session (Session 109).
PolyCol is a family of collagen mimetic peptides. STUART controls the worldwide rights for this technology in ophthalmology therapeutics. It acts as a rapid direct reparative to damaged collagen in situ, and is directly applicable where disease or trauma impacts important cells and their supporting underlying collagen membranes or structures. It improves and accelerates the recovery and repair of the cellular structures dependent upon that collagen, and acts to reduce inflammation.
About ARVO: The Association for Research in Vision and Ophthalmology is the largest and most respected eye and vision research organization in the world. Its members include nearly 12,000 researchers from over 75 countries. ARVO’s mission is to advance research worldwide into understanding the visual system and preventing, treating and curing its disorders. The 2020 ARVO Annual Meeting’s theme encompasses ARVO’s ultimate goal as vision scientists; to identify new treatments, new technologies and new approaches that prevent or treat conditions that affect the eye and vision. The presentations are selected through a rigorous abstract submittal process, and the focus of this year’s meeting is “Sight Saving Therapeutics.” It is anticipated that over 11,000 people will participate in this Meeting.
About Stuart Therapeutics: Stuart Therapeutics’ mission is to offer unique solutions for difficult-to-treat diseases of the eye. STUART is focused on the research and development of ophthalmic therapeutic products based on the company’s proprietary PolyCol Collagen Mimetic Peptide platform. STUART’s first drug in development is ST-100, targeting Dry Eye Disease (DED) and other ocular surface indications. In pre-clinical proof of concept testing, ST-100 has demonstrated accelerated repair of the epithelial layer, through binding of ST-100 to damaged sub-epithelial collagen layers. Complete repair of these tissues and the epithelial layer occurred within approximately 24 hours. ST-100 is expected to be broadly applicable to the patient population and should have therapeutic applications in patients regardless of the underlying cause of their DED. Other areas of application for PolyCol include dry age related macular degeneration, and neuroprotection, for which Stuart has also developed positive in vitro results.
For more information, please visit www.StuartTherapeutics.com